Literature DB >> 30929997

ATDC contributes to sustaining the growth and invasion of glioma cells through regulating Wnt/β-catenin signaling.

Yidong Cao1, Luoning Shi2, Maode Wang3, Juanru Hou4, Yanqiang Wei4, Changwang Du5.   

Abstract

Accumulating evidence has documented that ataxia-telangiectasia group D complementing gene (ATDC) is aberrantly expressed in various cancers and is associated with cancer development and progression. However, little is known about the role of ATDC in glioma tumorigenesis. In this study, we aimed to explore the biological function and regulatory mechanism of ATDC in glioma. We found that ATDC expression was highly upregulated in glioma cell lines. Knockdown of ATDC significantly inhibited the growth and invasion of glioma cells. In contrast, overexpression of ATDC markedly promoted the growth and invasion of glioma cells. Moreover, our results showed that inhibition of ATDC reduced the expression levels of Dishevelled 2 (Dvl2) and β-catenin and impeded the activation of Wnt/β-catenin signaling, whereas overexpression of ATDC showed the opposite effect. Knockdown of Dvl2 significantly blocked the promotion effect of ATDC overexpression on activation of Wnt/β-catenin signaling. In addition, silencing of β-catenin partially reversed the oncogenic effect of ATDC overexpression in glioma cells. Taken together, out study reveals an oncogenic role of ATDC that drives the growth and invasion of glioma by modulating the Wnt/Dvl2/β-catenin signaling pathway, suggesting a potential therapeutic target for treatment of glioma.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ATDC; Dvl2; Glioma; Wnt; β-catenin

Mesh:

Substances:

Year:  2019        PMID: 30929997     DOI: 10.1016/j.cbi.2019.03.033

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  3 in total

1.  Identification of a tripartite motif family gene signature for predicting the prognosis of patients with glioma.

Authors:  Sheng Xiao; Junhua Yu; Xuegang Yuan; Qianxue Chen
Journal:  Am J Transl Res       Date:  2022-03-15       Impact factor: 4.060

Review 2.  TRIM family contribute to tumorigenesis, cancer development, and drug resistance.

Authors:  Ning Huang; Xiaolin Sun; Peng Li; Xin Liu; Xuemei Zhang; Qian Chen; Hong Xin
Journal:  Exp Hematol Oncol       Date:  2022-10-19

3.  TRIM29 inhibits miR-873-5P biogenesis via CYTOR to upregulate fibronectin 1 and promotes invasion of papillary thyroid cancer cells.

Authors:  Tong Wu; Da-Lin Zhang; Jia-Mei Wang; Jing-Yi Jiang; Xin Du; Xiao-Yan Zeng; Zhen-Xian Du
Journal:  Cell Death Dis       Date:  2020-09-29       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.